BioRestorative Therapies (NASDAQ:BTRX) announced that Francisco Silva, the company’s chief scientist and vice president of research and development, has been appointed section editor of the newly launched Regenerative Medicine section of the prestigious Journal of Translational Medicine.
A peer-reviewed open-access medical journal, which has been published since 2003, the Journal of Translational Medicine had a 2021 impact factor of 8.440, ranking it among the top 3% of journals worldwide, according to Journal Citation Reports. It covers all areas of translational medicine but also has several special sections, Regenerative Medicine being its newest addition.
“We are excited to expand the journal’s focus on regenerative medicine and are thrilled to have found someone with Francisco’s demonstrated research excellence, pioneering clinical experience, and ability to serve as a respected ambassador to become our newest Section Editor,” said the journal’s Editor-in-Chief, Francesco Marincola, MD.
In a statement, Mr. Silva said, “I am deeply honored to have been selected to help launch this important new special section of the Journal of Translational Medicine. Today, most regenerative medicine research remains confined to the bench rather than the bedside. But if our cell-based therapy development progress at BioRestorative, as well as that at several other companies, is any indication, it may not be long before the full clinical potential of the field is realized. I am energized by this unique opportunity to work with my scientific colleagues from around the world to help fulfill that vision.”
Leveraging extensive experience in developing and translating cell-based therapeutics, Mr. Silva leads a team of scientists developing cell-based therapeutics targeting musculoskeletal and metabolic disorders at BioRestorative.
Currently, he is the principal investigator of an ongoing Phase 2 study investigating the use of BRTX-100, BioRestorative’s lead cell therapy clinical-stage candidate, in treating chronic lumbar disc disease (cLDD). More recently, Mr. Silva began developing BioRestorative’s novel allogeneic, off-the-shelf ThermoStem metabolic disease program. Through that work, he was the first to develop an artificial 3D brown adipose transplant using human brown adipose stem cells.
